The Food and Drug Administration told Merck & Co. that itrequires further safety and efficacy data before it will approve itssuccessor drug to now defunct pain reliever Vioxx, the pharmaceuticalmaker announced Friday.
Vioxx was taken off the market in September by Merck & Co. after aclinical trial using it was stopped because twice as many peopletaking the drug experienced cardiovascular disease than those taking aplacebo.
Pfizer Inc., the maker of two competingprescription drugs that are in the same class as Vioxx -- Celebrexand Bextra -- also has launched a big ad campaign.
